Impact of neoadjuvant chemotherapy on axillary nodal involvement in patients with clinically node negative triple negative breast cancer

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Journal of Surgical Oncology

• Publication date

  2015-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/jso.23790PMID 25266871
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.

  2014cited by this paper
• Surgeon specialization and use of sentinel lymph node biopsy for breast cancer.

  2014cited by this paper
• Changing surgical trends in young patients with early stage breast cancer, 2003 to 2010: a report from the National Cancer Data Base.

  2014cited by this paper
• Increasing National Mastectomy Rates for the Treatment of Early Stage Breast Cancer

  2013cited by this paper
• Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

  2013cited by this paper
• Are Breast Cancer Subtypes Prognostic for Nodal Involvement and Associated with Clinicopathologic Features at Presentation in Early-Stage Breast Cancer?

  2013cited by this paper
• Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.

  2012cited by this paper
• Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials

  2010cited by this paper
• American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.

  2010cited by this paper
• Effect of neoadjuvant anthracycline–taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study

  2010cited by this paper
• American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.

  2010cited by this paper
• Abstract P1-11-07: Results of a Phase II Study of Neoadjuvant Platinum/Taxane Based Chemotherapy and Erlotinib for Triple Negative Breast Cancer

  2010cited by this paper
• Research electronic data capture (REDCap) - A metadata-driven methodology and workflow process for providing translational research informatics support

  2009influential reference
• Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.

  2008cited by this paper
• Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence

  2007cited by this paper
• The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes

  2007cited by this paper
• Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial.

  2006cited by this paper
• Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors.

  2006cited by this paper
• Meta‐analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer

  2006cited by this paper
• Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer.

  2006cited by this paper
• Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.

  2005cited by this paper
• Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma

  2004cited by this paper
• The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.

  2003cited by this paper
• Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18.

  1997cited by this paper

• Factors Associated with Nodal Positivity Following Neoadjuvant Systemic Therapy in Breast Cancer Patients Who are Initially Node-Negative on MRI

  2025cites this paper
• Mass Spectrometry-Based Proteomics for Classification and Treatment Optimisation of Triple Negative Breast Cancer

  2024cites this paper
• Retrieval of the Clipped Axillary Lymph Node and Its Impact on Treatment Decisions

  2024cites this paper
• The Impact of Neoadjuvant Chemotherapy on Axillary Surgical Management of Patients With Breast Cancer and Positive Axillary Lymph Nodes

  2024cites this paper
• Prediction of Axillary Lymph Node Metastasis in Early-stage Triple-Negative Breast Cancer Using Multiparametric and Radiomic Features of Breast MRI.

  2023cites this paper
• Axillary Lymph Node Dissection Rates and Prognosis From Phase III Neoadjuvant Systemic Trial Comparing Neoadjuvant Chemotherapy With Neoadjuvant Endocrine Therapy in Pre-Menopausal Patients With Estrogen Receptor-Positive and HER2-Negative, Lymph Node-Positive Breast Cancer

  2021cites this paper
• Best Foot Forward: Neoadjuvant Systemic Therapy as Standard of Care in Triple-Negative and HER2-Positive Breast Cancer.

  2020cites this paper
• CCR2 signaling in breast carcinoma cells promotes tumor growth and invasion by promoting CCL2 and suppressing CD154 effects on the angiogenic and immune microenvironments

  2019cites this paper
• Update on the Treatment of Early-Stage Triple-Negative Breast Cancer

  2018cites this paper
• MRI and Prediction of Pathologic Complete Response in the Breast and Axilla after Neoadjuvant Chemotherapy for Breast Cancer.

  2017cites this paper
• Biology and Management of Patients With Triple-Negative Breast Cancer.

  2016cites this paper
• How Often Does Neoadjuvant Chemotherapy Avoid Axillary Dissection in Patients With Histologically Confirmed Nodal Metastases? Results of a Prospective Study

  2016cites this paper